Cargando…

Inhibiting the HIV Integration Process: Past, Present, and the Future

[Image: see text] HIV integrase (IN) catalyzes the insertion into the genome of the infected human cell of viral DNA produced by the retrotranscription process. The discovery of raltegravir validated the existence of the IN, which is a new target in the field of anti-HIV drug research. The mechanism...

Descripción completa

Detalles Bibliográficos
Autor principal: Di Santo, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926363/
https://www.ncbi.nlm.nih.gov/pubmed/24025027
http://dx.doi.org/10.1021/jm400674a
_version_ 1782303964979527680
author Di Santo, Roberto
author_facet Di Santo, Roberto
author_sort Di Santo, Roberto
collection PubMed
description [Image: see text] HIV integrase (IN) catalyzes the insertion into the genome of the infected human cell of viral DNA produced by the retrotranscription process. The discovery of raltegravir validated the existence of the IN, which is a new target in the field of anti-HIV drug research. The mechanism of catalysis of IN is depicted, and the characteristics of the inhibitors of the catalytic site of this viral enzyme are reported. The role played by the resistance is elucidated, as well as the possibility of bypassing this problem. New approaches to block the integration process are depicted as future perspectives, such as development of allosteric IN inhibitors, dual inhibitors targeting both IN and other enzymes, inhibitors of enzymes that activate IN, activators of IN activity, as well as a gene therapy approach.
format Online
Article
Text
id pubmed-3926363
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-39263632014-02-17 Inhibiting the HIV Integration Process: Past, Present, and the Future Di Santo, Roberto J Med Chem [Image: see text] HIV integrase (IN) catalyzes the insertion into the genome of the infected human cell of viral DNA produced by the retrotranscription process. The discovery of raltegravir validated the existence of the IN, which is a new target in the field of anti-HIV drug research. The mechanism of catalysis of IN is depicted, and the characteristics of the inhibitors of the catalytic site of this viral enzyme are reported. The role played by the resistance is elucidated, as well as the possibility of bypassing this problem. New approaches to block the integration process are depicted as future perspectives, such as development of allosteric IN inhibitors, dual inhibitors targeting both IN and other enzymes, inhibitors of enzymes that activate IN, activators of IN activity, as well as a gene therapy approach. American Chemical Society 2013-09-11 2014-02-13 /pmc/articles/PMC3926363/ /pubmed/24025027 http://dx.doi.org/10.1021/jm400674a Text en Copyright © 2013 American Chemical Society Terms of Use (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html)
spellingShingle Di Santo, Roberto
Inhibiting the HIV Integration Process: Past, Present, and the Future
title Inhibiting the HIV Integration Process: Past, Present, and the Future
title_full Inhibiting the HIV Integration Process: Past, Present, and the Future
title_fullStr Inhibiting the HIV Integration Process: Past, Present, and the Future
title_full_unstemmed Inhibiting the HIV Integration Process: Past, Present, and the Future
title_short Inhibiting the HIV Integration Process: Past, Present, and the Future
title_sort inhibiting the hiv integration process: past, present, and the future
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926363/
https://www.ncbi.nlm.nih.gov/pubmed/24025027
http://dx.doi.org/10.1021/jm400674a
work_keys_str_mv AT disantoroberto inhibitingthehivintegrationprocesspastpresentandthefuture